Circulating Residual Disease Assays for Real-Time Monitoring in Patients with Solid Tumors: A Pilot Study
Real time monitoring of disease status is vital for more effective cancer management. We report the utility of patient-specific digital droplet polymerase chain reaction (ddPCR) assays for monitoring the dynamics of patient (tumor) specific gene variants in circulating tumor DNA (ctDNA), and the longitudinal concordance of the observed variant frequencies (VF) with radiologically determined tumor burden (residual disease)